D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 80 Citations 28,250 605 World Ranking 9779 National Ranking 317

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Chemotherapy

Giuseppe Curigliano mainly focuses on Internal medicine, Breast cancer, Oncology, Cancer and Surgery. His Pathology research extends to the thematically linked field of Internal medicine. His biological study spans a wide range of topics, including Clinical endpoint and Adverse effect.

His Oncology research is multidisciplinary, incorporating perspectives in Pembrolizumab, Clinical trial, Chemotherapy, Phases of clinical research and Triple-negative breast cancer. His Cancer research is multidisciplinary, incorporating elements of Immunology, Intensive care medicine, Carcinoma, Melanoma and Disease. His work deals with themes such as Breast reconstruction, Adjuvant, Mastectomy and Hazard ratio, which intersect with Surgery.

His most cited work include:

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (1828 citations)
  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (879 citations)
  • Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy (608 citations)

What are the main themes of his work throughout his whole career to date?

Giuseppe Curigliano mostly deals with Internal medicine, Oncology, Breast cancer, Cancer and Chemotherapy. Giuseppe Curigliano combines topics linked to Surgery with his work on Internal medicine. His research in Surgery is mostly concerned with Radiation therapy.

The study incorporates disciplines such as Randomized controlled trial, Disease, Hazard ratio, Triple-negative breast cancer and Immunotherapy in addition to Oncology. His study in Breast cancer is interdisciplinary in nature, drawing from both Adjuvant, Immunology and Cancer research. His Cancer research incorporates themes from Immune system, Antigen and Intensive care medicine.

He most often published in these fields:

  • Internal medicine (69.16%)
  • Oncology (59.71%)
  • Breast cancer (51.97%)

What were the highlights of his more recent work (between 2019-2021)?

  • Internal medicine (69.16%)
  • Oncology (59.71%)
  • Breast cancer (51.97%)

In recent papers he was focusing on the following fields of study:

Internal medicine, Oncology, Breast cancer, Cancer and Clinical trial are his primary areas of study. His work in the fields of Chemotherapy, Metastatic breast cancer and Immunotherapy overlaps with other areas such as In patient. His research integrates issues of Precision medicine, Trastuzumab, Randomized controlled trial, Disease and Hazard ratio in his study of Oncology.

His Trastuzumab study integrates concerns from other disciplines, such as Biosimilar and Capecitabine. His studies in Breast cancer integrate themes in fields like Cancer research, Tumor-infiltrating lymphocytes and Family medicine. His Cancer research includes elements of Immune system and Intensive care medicine.

Between 2019 and 2021, his most popular works were:

  • A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. (236 citations)
  • Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (196 citations)
  • Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. (117 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Chemotherapy

Giuseppe Curigliano focuses on Internal medicine, Oncology, Cancer, Breast cancer and Disease. Giuseppe Curigliano interconnects Clinical trial, Trastuzumab, Metastatic breast cancer, Biomarker and Immunotherapy in the investigation of issues within Oncology. The concepts of his Clinical trial study are interwoven with issues in Pathological, Tolerability, Adverse effect, Triple-negative breast cancer and Drug resistance.

He has included themes like Cancer research, Risk of infection and Intensive care medicine in his Cancer study. His Breast cancer research includes elements of Chemotherapy, Tumor-infiltrating lymphocytes, Family medicine, Consensus conference and Anaplastic large-cell lymphoma. His studies examine the connections between Disease and genetics, as well as such issues in Seroconversion, with regards to Immunoglobulin G, Interquartile range and Observational study.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)

2956 Citations

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

F. Cardoso;A. Costa;E. Senkus;M. Aapro.
Annals of Oncology (2017)

879 Citations

Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

Daniela Cardinale;Alessandro Colombo;Giulia Bacchiani;Ines Tedeschi.
Circulation (2015)

833 Citations

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines

G. Curigliano;D. Cardinale;T. Suter;G. Plataniotis.
Annals of Oncology (2012)

750 Citations

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant.
Annals of Oncology (2018)

714 Citations

Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment

Marco Colleoni;Giuseppe Viale;David Zahrieh;Giancarlo Pruneri.
Clinical Cancer Research (2004)

425 Citations

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

M. V. Dieci;M. V. Dieci;C. Criscitiello;A. Goubar;G. Viale.
Annals of Oncology (2014)

381 Citations

A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.

Humaid O. Al-Shamsi;Waleed Alhazzani;Ahmad Alhuraiji;Eric A. Coomes.
Oncologist (2020)

365 Citations

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group Part 2 TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell.
Advances in Anatomic Pathology (2017)

330 Citations

Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management

Giuseppe Curigliano;Daniela Cardinale;Susan Dent;Carmen Criscitiello.
CA: A Cancer Journal for Clinicians (2016)

302 Citations

Editorial Boards

Annals of Oncology
(Impact Factor: 51.769)

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Giuseppe Curigliano

Giuseppe Viale

Giuseppe Viale

European Institute of Oncology

Publications: 118

Paolo Veronesi

Paolo Veronesi

European Institute of Oncology

Publications: 86

Marco Colleoni

Marco Colleoni

European Institute of Oncology

Publications: 85

Sherene Loi

Sherene Loi

Peter MacCallum Cancer Centre

Publications: 65

Nadia Harbeck

Nadia Harbeck

Ludwig-Maximilians-Universität München

Publications: 64

Carsten Denkert

Carsten Denkert

Philipp University of Marburg

Publications: 51

Dario Neri

Dario Neri

École Polytechnique Fédérale de Lausanne

Publications: 50

Giancarlo Pruneri

Giancarlo Pruneri

University of Milan

Publications: 49

Peter A. Fasching

Peter A. Fasching

University of Erlangen-Nuremberg

Publications: 48

Pierfranco Conte

Pierfranco Conte

University of Padua

Publications: 48

Fatima Cardoso

Fatima Cardoso

Champalimaud Foundation

Publications: 47

Andreas Schneeweiss

Andreas Schneeweiss

German Cancer Research Center

Publications: 47

Jonas Bergh

Jonas Bergh

Karolinska Institutet

Publications: 47

Javier Cortes

Javier Cortes

Vall d'Hebron Hospital Universitari

Publications: 45

Martine Piccart

Martine Piccart

Université Libre de Bruxelles

Publications: 44

Sibylle Loibl

Sibylle Loibl

Goethe University Frankfurt

Publications: 44

Something went wrong. Please try again later.